false
0001433607
0001433607
2026-11-13
2026-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): November 13, 2026
InspireMD,
Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
| 001-35731 |
|
26-2123838 |
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
6303
Waterford District Drive, Suite 215
Miami, Florida |
|
33126 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
(888)
776-6804
(Registrant’s
Telephone Number, Including Area Code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.0001 per share |
|
NSPR |
|
The
Nasdaq Capital Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry into a Material Definitive Agreement.
On
November 13, 2026, InspireMD, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”)
with Lake Street Capital Markets, LLC, as representative (the “Representative”) of the several underwriters named therein
(collectively, the “Underwriters”), relating to the issuance and sale in an underwritten public offering (the “Offering”)
of (i) 7,342,308 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common
Stock”), and pre-funded
warrants to purchase up to 50,350,000 shares of Common Stock (the “Pre-Funded Warrants”), and (ii) accompanying Series L
warrants to purchase up to 43,269,231 shares of Common Stock (or, at the election of the holder, pre-funded
warrants to purchase up to an equal number of shares
of Common Stock in lieu thereof) (the “Common
Warrants” and, together with the Pre-Funded Warrants, the “Warrants”), representing
75% of the aggregate number of Shares and Pre-Funded Warrants sold in the Offering.
Each Share is being sold together with an accompanying Common Warrant at a combined public offering price of $0.65, and each Pre-Funded
Warrant is being sold together with an accompanying Common Warrant at a combined public offering price of $0.6499, which equals the combined
public offering price per Share and accompanying Common Warrant, minus $0.0001.
Pursuant
to the Underwriting Agreement, the Company has agreed to pay the Underwriters an underwriting discount equal to 6.0% of
the gross proceeds of the Offering. All of the securities in the Offering are being sold by the Company.
Pursuant to the Underwriting Agreement, the Company also agreed to reimburse the Representative for certain expenses up to $125,000.
The
Underwriting Agreement contains customary representations, warranties and covenants by the Company, customary conditions to closing,
indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act, other obligations
of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were
made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may
be subject to limitations agreed upon by the contracting parties. Pursuant to the Underwriting Agreement, and subject to certain exceptions,
the Company has agreed not to issue or sell any shares of Common Stock or securities convertible into or exercisable or exchangeable
for Common Stock for a period beginning on the date of the Underwriting Agreement and ending 60 days following the closing of the Offering,
and not to effect or enter into any variable rate transactions for a period beginning on the date of the Underwriting Agreement and ending
six months following the closing of the Offering, in each case without the prior written consent of the Representative. In addition,
the Company’s executive officers and directors have agreed, subject to certain exceptions, not to sell or transfer any shares of
Common Stock or securities convertible into or exercisable or exchangeable for Common Stock for a period of 60 days from the date of
the Underwriting Agreement without the prior written consent of the Representative.
The
Company also granted the Representative a 30-day option to purchase up to 8,653,846 additional shares of Common Stock and/or
Pre-Funded Warrants to purchase up to 8,653,846 shares of Common Stock and/or Common Warrants to purchase up to 6,490,384 shares of
Common Stock (or Pre-Funded Warrants in lieu thereof) (or any combination thereof)
at the applicable public offering price minus underwriting discounts and commissions, representing 15% of the total number of
shares of Common Stock, Pre-Funded Warrants and
Common Warrants sold in the Offering, solely to cover over-allotment, if any.
Each
Pre-Funded Warrant has an exercise price of $0.0001 per share of Common Stock, is immediately exercisable upon issuance and may
be exercised at any time until exercised in full. Each Common Warrant has an exercise price of $0.65 per share of Common Stock, is immediately
exercisable upon issuance, will expire one year from the date of issuance and may be exercised, at the holder’s election,
for Pre-Funded Warrants in lieu of shares of Common Stock. A holder may not exercise any portion of its Warrants to the extent that the
holder, together with its affiliates and attribution parties, would beneficially own more than 4.99% (or, at the election of the holder,
9.99%) of the outstanding Common Stock immediately after exercise.
The
Common Warrants will be issued pursuant to a warrant agency agreement, dated as of November 12, 2026 (the “Warrant Agency
Agreement”), by and between the Company and Securities Transfer Corporation, as warrant agent.
The
Company estimates that the gross proceeds of the Offering will be approximately $37.5 million (or approximately $43.1 million
if the Representative exercises its option to purchase additional securities in full), prior to deducting underwriting discounts
and commissions and estimated offering expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the
Warrants. The Company intends to use the net proceeds from the Offering for the Company’s operations, including, but not limited
to, research and development, sales and marketing, working capital and other general corporate purposes.
The
closing of the Offering is expected to occur on or about November 16, 2026, subject to the satisfaction or waiver of customary
closing conditions.
The
Offering is being made pursuant to the Company’s effective shelf registration statement on Form S-3 (No. 333-286309), filed with
the Securities and Exchange Commission (“SEC”) on April 1, 2025, which became effective on April 10, 2025, and the base
prospectus included therein (the “Registration Statement”), as supplemented by preliminary prospectus supplement,
dated November 12, 2026, which was filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the
“Securities Act”), and a final prospectus supplement, dated November 13, 2026, relating to and describing the terms
of the Offering will be filed with the SEC pursuant to Rule 424(b) under the Securities Act on November 16, 2026.
The
Underwriting Agreement, the form of Pre-Funded Warrant, the form of Common Warrant and the Warrant Agency Agreement are filed as Exhibits
1.1, 4.1, 4.2 and 4.3, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. The foregoing descriptions
of the terms of the Underwriting Agreement, the Pre-Funded Warrants, the Common Warrants and the Warrant Agency Agreement are qualified
in their entirety by reference to such exhibits.
A
copy of the opinion, including the related consent, of Greenberg Traurig, P.A. relating to the legality of the issuance and sale of the
securities in the Offering is filed as Exhibit 5.1 hereto.
Item
8.01 Other Events.
On
November 13, 2026, the Company issued a press release to announce the pricing of the Offering (the “Pricing Press Release”).
A copy of the Pricing Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Forward
Looking Statements
This
Current Report on Form 8-K contains statements which constitute forward looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 and other securities laws. These forward looking statements are based upon the Company’s present
intent, beliefs or expectations, but forward looking statements are not guaranteed to occur and may not occur for various reasons, including
some reasons which are beyond the Company’s control. For example, this Current Report on Form 8-K states that the Offering is expected to close on or about November 16,
2026. In fact, the closing of the Offering is subject to various conditions and contingencies as are customary
in underwritten public offerings in the United States. If these conditions are not satisfied or the specified contingencies do not occur,
this Offering may not close. In addition, forward looking statements in this Current Report on Form 8-K also include the intended use
of proceeds from the Offering. For this reason, among others, you should not place undue reliance upon the Company’s forward looking
statements. Except as required by law, the Company undertakes no obligation to revise or update any forward looking statements in order
to reflect any event or circumstance that may arise after the date of this Current Report.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
| Exhibit
Number |
|
Description |
| 1.1 |
|
Underwriting Agreement, dated November 13, 2026, by and between InspireMD, Inc. and Lake Street Capital Markets, LLC, as representative of the several underwriters named therein |
| 4.1 |
|
Form of Pre-Funded Warrant to Purchase Common Stock |
| 4.2 |
|
Form of Series L Warrant to Purchase Common Stock |
| 4.3 |
|
Warrant Agency Agreement, dated November 12, 2026, by and between InspireMD, Inc. and Securities Transfer Corporation |
| 5.1 |
|
Opinion of Greenberg Traurig, P.A. |
| 23.1 |
|
Consent of Greenberg Traurig, P.A. (included in Exhibit 5.1) |
| 99.1 |
|
Pricing Press Release, dated November 13, 2026 |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
INSPIREMD,
INC. |
| |
|
| Date:
November 16, 2026 |
By: |
/s/
Marvin Slosman |
| |
Name: |
Marvin
Slosman |
| |
Title: |
Chief
Executive Officer |
Exhibit
99.1

InspireMD
Announces Pricing of $37.5 Million Public Offering
Miami,
FL -- November 13, 2026 — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer
of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the pricing of its previously announced underwritten
public offering of (i) 7,342,308 shares of its common stock, (ii) in lieu of common stock to certain investors, pre-funded warrants to
purchase 50,350,000 shares of its common stock, and (iii) accompanying common warrants to purchase 43,269,231 shares of its common stock
(or pre-funded warrants in lieu thereof). All securities in the offering are being offered by InspireMD.
In
addition, the Company granted the underwriters a 30-day option to purchase additional 8,653,846 shares of the Company’s common
stock and/or 8,653,846 pre-funded warrants and/or additional common stock warrants to purchase 6,490,384 shares of common stock (or pre-funded
warrants in lieu thereof) (or any combination thereof), representing 15% of the total number of shares of common stock and pre-funded
warrants sold in the offering, solely to cover over-allotments, if any.
The
offering is expected to close on or about November 16, 2026, subject to satisfaction of customary closing conditions.
Lake
Street Capital Markets is acting as the sole book runner for the offering.
InspireMD
intends to use the net proceeds from the offering, if any, for research and development, sales and marketing, working capital and other
general corporate purposes.
The
securities are being offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-286309) previously filed
with the U.S. Securities and Exchange Commission (the “SEC”) on April 1, 2025, and declared effective by the SEC on April
10, 2025. A preliminary prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC on November
12, 2026. Copies of the final prospectus supplement and accompanying base prospectus will be filed with the SEC and, when available,
may be obtained free of charge at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying base prospectus relating
to the offering may be obtained from Lake Street Capital Markets, LLC at 121 South Eighth Street, Suite 1000, Minneapolis, MN 55402,
or e-mail at prospectus@lakestreetcm.com.
This
press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor
shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful
prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About
InspireMD, Inc.
InspireMD
seeks to utilize its proprietary MicroNet ™ mesh technology to make its products the industry standard for carotid stenting by
providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under
the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information,
please visit www.inspiremd.com.

Forward-looking
Statements
This
press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements
regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future
financial performance, strategies, expectations, competitive environment and regulation. Such statements may be preceded by the words
“intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,”
“potential”, “scheduled” or similar words. These forward-looking statements include, but are not limited to,
statements regarding the closing of the offering and the anticipated use of proceeds.
In
particular, forward-looking statements in this press release include the Company’s expectations regarding the public offering,
including its anticipated completion, and the intended use of proceeds from the offering. Forward-looking statements are not guarantees
of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of
which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such
risks and uncertainties include, without limitation, risks associated with the public offering, including market conditions, the possibility
that the offering may not be completed on the anticipated terms or at all, and the Company’s ability to deploy any proceeds from
the offering as intended; risks and uncertainties associated with the voluntary U.S. recall of the CGuard Prime 135 cm delivery system,
including current and future costs associated with the recall, including refunds or inventory write-off costs and other remediation costs,
loss of sales and customers due to the recall or otherwise, our ability to effectively implement enhancements to CGuard Prime 135 cm
delivery system, potential actions by regulators or other governmental entities associated with the recall, potential claims and lawsuits
by customers and patients, including class action product liability lawsuits, other operational impacts and consequences of the recall,
such as business disruption and distraction of management and other key employees; the Company’s history of recurring losses and
negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of its liquidity
to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; the Company’s
need to raise additional capital to meet its business requirements in the future and such capital raising may be costly or difficult
to obtain and could dilute our stockholders’ ownership interests; the clinical development, commercialization and market acceptance
of the Company’s products; whether the clinical trial results for the Company’s products will be predictive of real-world
results; an inability to secure and maintain regulatory approvals for the sale of the Company’s products; negative clinical trial
results or lengthy product delays in key markets; the Company’s ability to maintain compliance with the Nasdaq listing standards;
the Company’s ability to generate significant revenues from its products; estimates of the Company’s expenses, future revenues,
capital requirements and its needs for and ability to access sufficient additional financing, including any unexpected costs or delays
in the ongoing commercial launch of its products; the Company’s dependence on a single manufacturing facility and its ability to
comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from
the Company’s current and planned clinical trials may not be sufficient to demonstrate that its technology is an attractive alternative
to other procedures and products; intense competition in the Company’s industry, with competitors having substantially greater
financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel
resources than it does; entry of new competitors and products and potential technological obsolescence of the Company’s products;
inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with
the Company’s research and products and potential product liability claims; product malfunctions; price increases for supplies
and components; whether access to the Company’s products is achieved in a commercially viable manner and whether its products receive
adequate reimbursement by governmental and other third-party payers; the Company’s efforts to successfully obtain and maintain
intellectual property protection covering its products, which may not be successful; adverse federal, state and local government regulation,
in the United States, Europe or Israel and other foreign jurisdictions; the fact that the Company conducts business in multiple foreign
jurisdictions, exposing it to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs
of compliance with foreign laws and political and economic instability in each jurisdiction; security, political and economic instability
in the Middle East that could harm the Company’s business, including due to the current security situation in Israel; current or
future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity
risk; and changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements and the impact of such policies
on the Company, its customers and suppliers, and the global economic environment.
More
detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth
in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s
web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result
of new information, future events or otherwise.
Investor
Contact
Investor
Contacts:
Jeff
Warren
LifeSci
Advisors
jwarren@lifesciadvisors.com
investor-relations@inspiremd.com